Home/Filings/4/0000950170-24-042607
4//SEC Filing

Perlich Irene 4

Accession 0000950170-24-042607

CIK 0001426332other

Filed

Apr 7, 8:00 PM ET

Accepted

Apr 8, 4:14 PM ET

Size

19.6 KB

Accession

0000950170-24-042607

Insider Transaction Report

Form 4
Period: 2024-04-05
Perlich Irene
Principal Accounting Officer
Transactions
  • Disposition from Tender

    Common Stock

    2024-04-056,2840 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-04-0550,0000 total
    Exercise: $0.84Exp: 2031-03-31Common Stock (50,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-04-0535,0000 total
    Exercise: $0.84Exp: 2032-03-02Common Stock (35,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-04-0520,0000 total
    Exercise: $1.07Exp: 2033-09-30Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-04-0517,5000 total
    Exercise: $0.84Exp: 2032-11-03Common Stock (17,500 underlying)
  • Disposition to Issuer

    Restricted Stock Unit

    2024-04-057,5000 total
    Common Stock (7,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-04-0530,0000 total
    Exercise: $4.36Exp: 2033-03-01Common Stock (30,000 underlying)
Footnotes (4)
  • [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").
  • [F2]Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, as of the Effective Time, each outstanding Restricted Stock Unit was canceled and the holder of such canceled Restricted Stock Unit was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the Offer Price.
  • [F3]Restricted Stock Units do not have an expiration date.
  • [F4]Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

Documents

1 file

Issuer

NGM BIOPHARMACEUTICALS INC

CIK 0001426332

Entity typeother

Related Parties

1
  • filerCIK 0001989954

Filing Metadata

Form type
4
Filed
Apr 7, 8:00 PM ET
Accepted
Apr 8, 4:14 PM ET
Size
19.6 KB